Massachusetts Institute of Technology

Boston University

Senti Biosciences, Inc.

Timothy Kuan-Ta Lu

James Joseph Collins

Sebastien Lemire

Philip Janmin Lee

Robert James Citorik

Russell Morrison Gordley

Brian Scott Garrison

Don-Hong Wang

Jack Tzu-Chiao Lin

Alba Gonzalez-Junca

Kevin Yehl

Daniel Frimannsson

Russell-John Krom

Sara Da Luz Areosa Cleto

Andrew C Yang

Mark Kyle Mimee

Hiroki Ando

Allen Yuyin Chen

Gregory N Stephanopoulos

Xuanhe Zhao

Christopher A Voigt

Hideki Kobayashi

Paul Brown

Sahag Voskian

T Alan Hatton

Ari E Friedland

Manolis Kellis

Michael Koeris

Zhizhuo Zhang

Cesar De La Fuente Nunez

Zhengtao Deng

Allen Cheng

Mads Kearn

Michihiro Araki

Alex C Tucker

Lior Nissim

Ming-Ru Wu

Eléonore Claire Tham

Tzu-Chieh Tang

Xinyue Liu

Jicong Cao

Eva Maria Novoa Pardo

Tanguy My Chau

Christopher Jongsoo Yoon

Nathaniel B Roquet

Chao Zhong

Piro Siuti

Ching Gee Choi

Alan Siu Lun Wong

Disclosed herein are novel 5′ UTR sequences that can be used to control gene expression in various contexts. Also disclosed herein are methods of engineering 5′ UTR sequences and methods and kits for screening 5′ UTR sequences for a property of interest.

Synthetic 5' UTR sequences, and high-throughput engineering and screening thereof

Provided herein, in some embodiments, are hydrogel-elastomer and hydrogel-alginate devices, compositions and associated methods to encapsulate living cells.

Materials and devices containing hydrogel-encapsulated cells

Synthetic promoters that are differentially modulated between certain diseased cells (e.g., cancer cells) and normal cells (e.g., non-cancer cells) are described. The synthetic promoters may be used to drive expression of gene(s) of interest in a specific cell type or during a specific cellular state. These synthetic promoters are useful, for example, for targeted expression of therapeutic molecules in diseased cells.

Synthetic promoters

Provided herein, in some aspects, are tools (e.g., methods, compositions and nucleic acids) for building genetic circuits inandbacteria, as well as the bacteria containing the genetic circuits.

Gene expression in Bacteroides

Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.

Combinatorial cancer immunotherapy

Disclosed here are recombinant bacteriophages with tail fibers encoded by at least two subsets of genomic fragments from different bacteriophage having different host ranges.

Tuning bacteriophage host range

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

Synthetic bacteriophages and bacteriophage compositions

Disclosed are methods of antimicrobial treatment using ionic liquids (ILs), IL complexes, polymers comprising ILs, and polymers comprising neutral ethylene diamine compounds. Also disclosed are novel IL complexes, polymers comprising ILs, and polymers comprising neutral ethylene diamine compounds.

Silver- and copper-chelating ionic liquids, polymers, and gels, and uses thereof

Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.

Functionalization of endogenous bacteria

Compositions and methods using shufflon recombinases are presented for use in generating genetic diversity in molecules of interest.

Methods and compositions for recombinase-based genetic diversification

Provided herein are synthetic pathways fromandgenes for the production of new, synthetic nonribosomal peptides, and methods and compositions comprising the same. Some aspects of the present disclosure are directed to modified bacterial cells comprising a compressed biosynthetic pathway that comprises (a) biosynthetic genes obtained from one species encoding enzymes active in the bioassembly of a nonribosomal molecule, (b) biosynthetic genes obtained from another species encoding enzymes active in the bioassembly of a nonribosomal molecule that is different from the nonribosomal molecule of (a). In some embodiments, the biosynthetic genes of (a) arebiosynthetic genes and may include entD gene, an entC gene, an entE gene, an entB gene and an entA gene. In some embodiments, the biosynthetic genes of (b) arebiosynthetic genes and may include a vibH gene and a vibF gene.

Compressed pathways for nonribosomal molecular biosynthesis

Various aspects and embodiments of the invention are directed to methods and compositions for reversing antibiotic resistance or virulence in and/or destroying pathogenic microbial cells such as, for example, pathogenic bacterial cells. The methods include exposing microbial cells to a delivery vehicle with at least one nucleic acid encoding an engineered autonomously distributed circuit that contains a programmable nuclease targeted to one or multiple genes of interest.

Tuning microbial populations with programmable nucleases

Provided herein are genetic constructs comprising genetic perturbation cassettes and methods of using such to assess the timing and order of gene expression.

Extensible recombinase cascades

Growing community of inventors

Cambridge, MA, United States of America

Timothy Kuan-Ta Lu